SG11201901325UA - Dosage regimen for treatment of solid tumors - Google Patents
Dosage regimen for treatment of solid tumorsInfo
- Publication number
- SG11201901325UA SG11201901325UA SG11201901325UA SG11201901325UA SG11201901325UA SG 11201901325U A SG11201901325U A SG 11201901325UA SG 11201901325U A SG11201901325U A SG 11201901325UA SG 11201901325U A SG11201901325U A SG 11201901325UA SG 11201901325U A SG11201901325U A SG 11201901325UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- eli lilly
- applicant
- pct
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/048308 WO2018044662A1 (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901325UA true SG11201901325UA (en) | 2019-03-28 |
Family
ID=59772787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901325UA SG11201901325UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
| SG10202107832UA SG10202107832UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202107832UA SG10202107832UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (es) |
| EP (1) | EP3506905B1 (es) |
| JP (2) | JP2019526632A (es) |
| KR (1) | KR102512899B1 (es) |
| CN (2) | CN116473978A (es) |
| AU (1) | AU2017321011B2 (es) |
| BR (1) | BR112019002461A2 (es) |
| CA (1) | CA3035616A1 (es) |
| ES (1) | ES2977556T3 (es) |
| IL (2) | IL264924B2 (es) |
| MA (1) | MA46086A (es) |
| MX (1) | MX2019002066A (es) |
| SG (2) | SG11201901325UA (es) |
| WO (1) | WO2018044662A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| ES2898952T3 (es) | 2016-04-12 | 2022-03-09 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| SG11201810268YA (en) | 2016-05-20 | 2018-12-28 | Lilly Co Eli | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| WO2008112249A1 (en) * | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| EP3354276B1 (en) * | 2007-11-13 | 2020-01-01 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| JP2017526641A (ja) * | 2014-07-11 | 2017-09-14 | ジェネンテック， インコーポレイテッド | Ｎｏｔｃｈ経路阻害 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
-
2017
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 MX MX2019002066A patent/MX2019002066A/es unknown
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/ko active IP Right Grant
- 2017-08-24 MA MA046086A patent/MA46086A/fr unknown
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/ja active Pending
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/zh active Pending
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en unknown
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/zh active Pending
- 2017-08-24 ES ES17761723T patent/ES2977556T3/es active Active
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/pt unknown
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en active Active
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en active Pending
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109562114A (zh) | 2019-04-02 |
| MX2019002066A (es) | 2019-06-03 |
| CN116473978A (zh) | 2023-07-25 |
| IL264924B1 (en) | 2023-09-01 |
| JP2019526632A (ja) | 2019-09-19 |
| AU2017321011B2 (en) | 2023-08-03 |
| AU2017321011A1 (en) | 2019-02-21 |
| MA46086A (fr) | 2019-07-10 |
| SG10202107832UA (en) | 2021-09-29 |
| IL264924A (es) | 2019-04-30 |
| ES2977556T3 (es) | 2024-08-26 |
| BR112019002461A2 (pt) | 2019-05-14 |
| CA3035616A1 (en) | 2018-03-08 |
| IL264924B2 (en) | 2024-01-01 |
| WO2018044662A1 (en) | 2018-03-08 |
| EP3506905A1 (en) | 2019-07-10 |
| KR20190042591A (ko) | 2019-04-24 |
| KR102512899B1 (ko) | 2023-03-23 |
| EP3506905B1 (en) | 2024-03-20 |
| JP2023052108A (ja) | 2023-04-11 |
| IL305136A (en) | 2023-10-01 |
| US20190209581A1 (en) | 2019-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901325UA (en) | Dosage regimen for treatment of solid tumors | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201907891XA (en) | Combination therapy for the treatment or prevention of tumours | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201807543YA (en) | Hepatitis b antiviral agents | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201810268YA (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |